Shinobi Therapeutics is a biotechnology startup founded in 2023 and headquartered in the United States. The company is focused on developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond, leveraging immune evasion to unlock the full potential of iPSCs.
The startup recently secured a significant $51.00M Series A investment on 12 December 2023. This round of funding involved a consortium of notable investors including F-Prime Capital, Life Science Partners, Astellas Venture Management, JIC Venture Growth Investments, D3, Fast Track Initiative, Inc., and Eight Roads Ventures Japan.
Overall, Shinobi Therapeutics' innovative approach and substantial Series A investment showcase its potential for advancing cutting-edge biotechnological solutions in the fight against cancer and potentially other diseases.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $51.00M | 7 |
|
12 Dec 2023 |
No recent news or press coverage available for Shinobi Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
